Daxor Corporation, a provider of blood volume measurement technology, has announced expansion of blood volume analysis (BVA) into five of six hospitals in the Southeast and increased utilization for clinical use at two sites to guide fluid management in patients during the second quarter of 2023. The recent launch of Daxor’s ezBVA Lab service at quarter-end is anticipated to contribute significantly to growth of BVA sales, while providing additional validation for the use of BVA in the coming quarters based upon the pipeline of leads that have already expressed interest in the new offering.
A six-facility hospital system currently operating throughout Northern Kentucky and Southeastern Indiana with 169 physician specialty and primary care offices has begun utilizing Daxor’s ezBVA Lab service—a state-of-the-art CLIA-certified facility located at Daxor’s Oak Ridge facility that provides on-demand, next day blood volume analysis results for their heart failure clinic patients. The hospital system is finding the diagnostic highly effective to optimize care for their heart failure population and a growing cohort of clinicians are gaining expertise with BVA technology.
“Expanding commercialization with the addition of new hospital systems, new treatment areas, and growing clinical and health economic evidence of the benefit our diagnostic provides remains one our key priorities,” says Michael Feldschuh, Daxor’s CEO and president. “The recent launch of our ezBVA Lab service, which reduces test-related overhead and labor, is expected to accelerate adoption and enhance greater prescriber access to our BVA technology in the second half of this year.”
Further Reading: Daxor Launches ezBVA Lab Services for Blood Volume Analysis
Two additional hospitals have expanded the use of BVA testing highlighting the importance of blood volume analysis use in the clinical setting. A leading hospital and academic center in New York, ranked in the top three in the country according to the U.S. News & World Report’s annual 2022 “Best Hospitals”, has begun offering the BVA testing to patients with dysautonomia, a group of medical conditions caused by problems with the autonomic nervous system of which blood volume derangements are often common and go undiagnosed. A second top-ranked facility in central Pennsylvania serving more than one million people through ten hospital campuses, a health plan with more than half a million members, a research institute and the College of Health Sciences, has expanded its use of BVA-100 for its cardiac amyloid patients—a rare condition that impacts the ability of the heart to function properly causing blood volume abnormalities that can only be quantified using blood volume analysis.
“We have a robust sales pipeline going into the second half of 2023, fueled by our team of sales and clinical experts, and customers choosing to use Daxor’s ezBVA Lab service—which provides a quicker solution to solve the challenges of hospital readmissions and length of stay without the need for upfront investment. It seamlessly integrates into existing workflows, and facilitates easier access to BVA,” says Jean Oertel, Daxor’s sr. vice president of Commercialization and Customer Experience.
